trial · primary record
Glofitamab
Non-Hodgkins Lymphoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 211 |
| Primary completion | 2026-10-22 |
| Primary endpoint | Best Objective Response Rate (ORR) as Measured by Independent Review Committee (IRC) |
| Registry ID | NCT03533283 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:43:30.820Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03533283
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.